EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Genomic Correlates of APOBEC ‐Associated Mutagenesis in Esophageal Squamous Cell Carcinoma

Emmanuel Owusu Ansah, Joshua Ampofo Yentumi, Emmanuel Yeboah Kodom, Prince Owusu Mensah, Kwadwo Fosu, Isaac Kofi Adu, Emmanuel Adu Boahen

Molecular Genetics & Genomic Medicine · 2026-11 · 14 (11)

DOI: 10.1002/mgg3.70345 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background and Aims APOBEC‐associated mutagenesis is prominent in esophageal squamous cell carcinoma (ESCC), but genomic features associated with its intertumoral variability remain incompletely characterized. We investigated genomic correlates of APOBEC‐associated mutagenesis while accounting for the compositional structure of mutational signature data. Methods Mutational signatures were analyzed in 552 ESCC tumors from eight countries. APOBEC‐associated mutagenesis was quantified as SBS2 plus SBS13 using absolute mutation counts and proportional contributions. Associations with co‐occurring mutational signatures, total SBS burden, recurrent driver‐gene alterations, and country were evaluated using correlation, sensitivity, and multivariable analyses. Principal component and regression‐model robustness were additionally assessed. Results APOBEC burden varied markedly across tumors (median, 2002 mutations; IQR, 987–4346). Several associations observed using signature proportions were not maintained in absolute‐count analyses: SBS1, SBS3, and SBS5 changed direction, indicating sensitivity to compositional representation. In contrast, SBS18 remained inversely associated with APOBEC‐associated mutagenesis in all variable pairings examined: proportion vs. proportion (Spearman ρ = −0.527), APOBEC proportion vs. SBS18 absolute count ( r = −0.435), and absolute count vs. absolute count (Pearson r = −0.319, p = 1.59 × 10 −14 ; Spearman ρ = −0.317). These are distinct comparisons rather than discrepant estimates. Notably, this cohort‐wide relationship was primarily characterized by higher APOBEC burden in SBS18‐negative than SBS18‐positive tumors rather than a continuous inverse relationship among SBS18‐positive tumors. The multivariable model had an in‐sample R 2 of 0.400 but lower and variable 10‐fold cross‐validated performance (mean R 2 = 0.273). Country added little explanatory information to this model (Δ R 2 = 0.008; global p = 0.402). ZNF750‐mutant tumors had higher APOBEC burden than wild‐type tumors (BH‐FDR q = 0.0032), although only 12 tumors carried ZNF750 alterations. Conclusion Genomic correlates of APOBEC‐associated mutagenesis in ESCC are sensitive to the representation of mutational signature activity. SBS18 showed the most consistent inverse association, whereas the ZNF750 association warrants independent validation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →